Apollo Hospitals Enterprise Limited · NSE:APOLLOHOSP
Apollo Hospitals Enterprise — Q2 FY2022 Earnings Presentation
31 slides from Apollo Hospitals Enterprise's earnings presentation, Nov 13, 2021
Slide 1: Apollo Hospitals Enterprise Limited – Regulation 30 Disclosure Letter
APOLLO HOSPITALS ENTERPRISE LIMITED CIN : L85110TN1979PLC008035 ApolloH OS P ITALS TOUCHING LIVES 13th November 2021 The Secretary, The Secretary, The Manager Bombay Stock Exchange Ltd (BSE) National Stock Exchange, The National Stock Phiroze Jheejheebhoy Towers, Exchange Plaza, 5th Floor Exchange,
Slide 2: Earnings Update Q2 FY 2022
EARNINGS UPDATE Q2 FY 2022 1
Slide 3: Disclaimer
DISCLAIMER • No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the
Slide 4: Key Highlights
Key Highlights HIGHLIGHTS CONSOLIDATED FINANCIAL STANDALONE FINANCIAL PERFORMANCE PERFORMANCE OPERATIONAL PARAMETERS - APOLLO 24/7 APOLLO HEALTH & LIFESTYLE LTD HOSPITALS & PHARMACIES 3
Slide 5: Highlights
HIGHLIGHTS i
Slide 6: Highlights
HIGHLIGHTS Q2 FY22 Consolidated Revenues of ` 37,171 mio (growth of 35% yoy). Q2 FY22 Consolidated EBITDA (Post Ind AS 116) of ` 6,150 mio. Financial New Hospitals (excl Proton) reported an EBITDA of ` 1,277 mio in Q2 FY22 as compared to an EBITDA of ` 387 mio in Q2 FY21. Performance Q2 FY22
Slide 7: Highlights
HIGHLIGHTS 71 hospitals with total bed capacity of 10,231 beds as on September 30, 2021. 44 owned hospitals including JVs/ Subsidiaries and Associates with 8,858 beds. 11 Day care/ short surgical stay centres with 244 beds and 11 Cradles with 278 beds. Capacity 5 Managed hospitals with 851 b
Slide 8: COVID Testing and Treatment – H1FY22
COVID TESTING AND TREATMENT – H1FY22 ‘Project Stay I’ saw success with over 24,000 1,800+ 28,500 + room nights. Dedicated beds In -Patients 2,900+ Stay I Our effort in the Home care segment enabled us to move into 49,000 homes, (of which COVID care was at 22,000 homes) and provide medically supe
Slide 9: Consolidated Financial Performance
CONSOLIDATED FINANCIAL PERFORMANCE
Slide 10: Consolidated Financial Performance
CONSOLIDATED FINANCIAL PERFORMANCE TOTAL (` mio) Q2 FY 21 Q2 FY 22 yoy (%) H1 FY 21 H1 FY 22 yoy (%) Total Revenues 27,607 37,171 34.6% 49,322 74,773 51.6% EBITDA (Post Ind AS 116) 2,998 6,150 105.1% 3,353 11,349 238.5% margin (%) 10.9% 16.5% 568 bps 6.8% 15.2% 838 bps EBIT 1,504 4,702 212.7% 257 8,
Slide 11: Consolidated Financial Performance – Mature & New Breakup Q2 FY22
CONSOLIDATED FINANCIAL PERFORMANCE MATURE & NEW BREAKUP – Q2 FY22 (` mio) Healthcare Key Highlights Healthcare Healthcare Serv Serv Serv Pharmacy Group Proton AHLL Consol HCS revenue grew by 75% in Q2FY22 Group Group Distribution* (New & (Mature) (Total) Others) Hospitals 30 13 1 44 HCS EBITDA at `
Slide 12: Consolidated Financial Performance – Mature & New Breakup H1 FY22
CONSOLIDATED FINANCIAL PERFORMANCE MATURE & NEW BREAKUP – H1 FY22 (` mio) Healthcare Healthcare Healthcare Key Highlights Serv Serv Serv Pharmacy Group Proton AHLL Consol Group (New & Group Distribution* HCS revenue grew by 103% in H1FY22 (Mature) (Total) Others) Hospitals 30 13 1 44 Operating beds
Slide 13: Standalone Financial Performance
STANDALONE FINANCIAL PERFORMANCE
Slide 14: Standalone Financial Performance
STANDALONE FINANCIAL PERFORMANCE (` mio) TOTAL Q2 FY 21 Q2 FY 22 yoy (%) H1 FY 21 H1 FY 22 yoy (%) Revenue 24,144 28,232 16.9% 43,760 58,179 33.0% Operative Expenses 14,265 16,275 14.1% 25,968 34,699 33.6% Employee Expenses 3,364 3,200 -4.9% 7,132 6,381 -10.5% Administrative & Other Expenses 4,033 4
Slide 15: Standalone Financial Performance – Mature & New Breakup Q2 FY22
STANDALONE FINANCIAL PERFORMANCE MATURE & NEW BREAKUP – Q2 FY22 (` mio) (` mio) Key Highlights Healthcare Healthcare Pharmacy Service New Services Standalone Distribution* HCS revenue grew by 56% in Q2FY22 (Mature) Hospitals Proton (Total) Hospitals 21 10 1 32 Operating beds 3,294 1,609 53 4,956 Occ
Slide 16: Standalone Financial Performance – Mature & New Breakup H1 FY22
STANDALONE FINANCIAL PERFORMANCE MATURE & NEW BREAKUP –H1FY22 (` mio) Healthcare Healthcare New Pharmacy Key Highlights Service Proton Services Standalone Hospitals Distribution* (Mature) (Total) Hospitals 21 10 1 32 HCS revenue grew by 80% in Operating beds 3,294 1,609 53 4,956 H1FY22 Occupancy 63%
Slide 17: Standalone Financial Performance – Segment Reporting
STANDALONE FINANCIAL PERFORMANCE SEGMENT REPORTING (` mio) Q2 FY 21 Q2 FY 22 yoy (%) H1 FY 21 H1 FY 22 yoy (%) Revenues from each segment Healthcare Services* 10,626 16,561 55.8% 17,451 31,388 79.9% Stand-alone Pharmacy 9,907 0 22,698 0 Pharmacy Distribution** 3,612 11,671 3,612 26,791 Total 24,145
Slide 18: Operational Parameters - Hospitals & Pharmacies
OPERATIONAL PARAMETERS - HOSPITALS & PHARMACIES
Slide 19: Operational Parameters - Hospitals
OPERATIONAL PARAMETERS - HOSPITALS (` mio) Tamilnadu Region AP, Telengana Region Karnataka Region Significant Subs/JVs/associates Total (6) Others (4) (Chennai & others) (1) (Hyderabad & others) (2) (Bangalore & others) (3) (5) Particulars H1 FY 21 H1 FY 22 yoy (%) H1 FY 21 H1 FY 22 yoy (%) H1 FY 21
Slide 20: Pharmacy Distribution
PHARMACY DISTRIBUTION (` mio) Pharmacy Distribution Q2 FY 21 Q2 FY 22 yoy (%) H1 FY 21 H1 FY 22 yoy (%) Revenue 13,519 11,671 -13.7% 26,310 26,791 1.8% EBITDA (Post Ind AS 116)** 1,156 945 -18.3% 2,376 2,097 -11.7% margin (%) 8.6% 8.1% -46 bps 9.0% 7.8% -120 bps *Pharmacy Distribution from 1st Sep 2
Slide 21: Apollo 24/7
APOLLO 24/7 i
Slide 22: Apollo 24/7 – India's Largest Omni-Channel Healthcare Platform
APOLLO 24X7 – INDIA’S LARGEST OMNI-CHANNEL HEALTHCARE PLATFORM LEVERAGING PHYSICAL NETWORK Distinctive digital 5 ecosystem … 4 Condition 6 management Digital services Online Health diagnostic predictor 3 booking 7 Well-being Part of Virtual doctor companion consultation Apollo 24/7 2 Online 8 Health
Slide 23: Distinctive Digital Ecosystem Coupled with Physical Network
Distinctive digital ecosystem… … coupled with adequate network and capabilities Cumulative upto 30th Sep 2021 Physical network & capabilities ~7.3 Lakh+ 1 2 3 Doctors across 3mm+ Annual Online Consults Diagnostic centers Hospitals & clinics chronic patients ~12 Mn completed 4 5 Registrations Leverag
Slide 24: Apollo HealthCo
APOLLO HEALTHCO Reorganization through Slump Sale AHEL (Listed) • Apollo 24/7 represents Apollo Group’s transformational journey to creating “India’s Largest Omnichannel Digital Healthcare Platform” that: Backend combines the strengths of Apollo Group’s offline healthcare Healthcare Pharmacy + lea
Slide 25: Apollo Health & Lifestyle Ltd
APOLLO HEALTH & LIFESTYLE LTD
Slide 26: AHLL – Q2 FY22
AHLL – Q2 FY22 (` mio) Key Highlights Spectra Clinics Diagnostics Sugar Dental Dialysis Cradles (IP) IVF (IP) Network 226 985 22 68 81 8 14 11 AHLL reported EBITDA of ` 621 Footfalls/Day* 9297 12153 424 174 1166 46 19 76 mio as compared to ` 212 mio Gross ARPP (Rs.)* 1244 578 3024 6349 1512 99374 39
Slide 27: AHLL – H1 FY22
AHLL – H1 FY22 (` mio) Spectra Key Highlights Clinics Diagnostics Sugar Dental Dialysis Cradles (IP) IVF (IP) Network 226 985 22 68 81 8 14 11 AHLL reported EBITDA of Footfalls/Day* 8047 13074 363 126 1131 42 17 64 ` 1,101 mio as compared Gross ARPP (Rs.)* 1210 595 2733 6454 1500 102555 37933 104185
Slide 28: Strategic Portfolio Approach for AHLL
STRATEGIC PORTFOLIO APPROACH FOR AHLL Accelerated Growth Continued Growth as per plan Sustainability and Asset Light Growth Aim for market leadership Established player Sustained growth with synergies to the Focus on enhancing market share across India Focus on improving capabilities and opportunist
Slide 29: Appendix: Ind AS 116 Impact on P&L and Balance Sheet – H1FY22
APPENDIX 1 : IND AS - 116 IMPACT ON P&L AND BALANCE SHEET – H1FY22 (` mio) AHEL Standalone (post IND AS 116) AHEL Consolidated (post IND AS 116) Balance sheet Profit & Loss Balance sheet Profit & Loss Revenue - Right of use Revenue Right of use Asset as of 5,884 Asset as of 10,381 Other 428 Other ex
Slide 30: Appendix: Basis of Consolidation
APPENDIX 2 : BASIS OF CONSOLIDATION AHEL Standalone Location Description AHEL Ownership AHEL Chennai Main Chennai Hospital Subsidiaries Location Description Ownership ACI - Chennai Chennai Hospital Samudra Healthcare Enterprises Ltd. Kakinada Hospital 100.00% Tondiarpet - Chennai Chennai Hospital Ap
Slide 31: Thank You
THANK YOU 30
Apollo Hospitals Enterprise — Q2 FY2022 Earnings Presentation on 6ix